Basic information Safety Supplier Related

RVX297

Basic information Safety Supplier Related

RVX297 Basic information

Product Name:
RVX297
Synonyms:
  • RVX297
  • 4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5,7-dimethoxy-
  • 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one
  • autoimmunity,RVX 297,proinflammatory,Epigenetic Reader Domain,RVX-297,immune,inhibit,mediator,inflammatory,Inhibitor,selectivity,acute,cell,arthritis
  • 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(1H)-one
  • 2-{3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,7-dimethoxy-1,4-dihydroquinazolin-4-one
  • 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one , RVX-297
  • RVX-297, 10 mM in DMSO
CAS:
1044871-04-6
MF:
C24H29N3O4
MW:
423.5
Mol File:
1044871-04-6.mol
More
Less

RVX297 Chemical Properties

Boiling point:
612.6±65.0 °C(Predicted)
Density 
1.25±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO : 50 mg/mL (118.06 mM; Need ultrasonic)
pka
9.54±0.20(Predicted)
form 
Solid
color 
White to light brown
More
Less

RVX297 Usage And Synthesis

Uses

RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2. RVX-297 shows IC50s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models[1][2].

in vivo

RVX-297 (25-75 mg/kg; p.o.; per day for 6 day) inhibits progression of pathology in the rat collagen-induced arthritis model[1].
RVX-297 (75-150 mg/kg) inhibits progression of pathology in the mouse collagen-induced arthritis model[1].
RVX-297 suppresses cytokine production in LPS-treated mice[1].

Animal Model:Female Lewis rats are 6-8 weeks old, approximately 150 g (rat collagen-induced arthritis)[1]
Dosage:25, 50, and 75 mg/kg
Administration:P.o.; per day for 6 days
Result:Prevented swelling and inflammation of the ankle and knee joints.

IC 50

BRD2 (BD1): 3.76 μM (IC50); BRD2 (BD2): 0.08 μM (IC50); BRD3 (BD1): 2.34 μM (IC50); BRD3 (BD2): 0.05 μM (IC50); BRD4 (BD1): 1.16 μM (IC50); BRD4 (BD2): 0.02 μM (IC50); BRDT (BD1): 2.69 μM (IC50)

References

[1] Jahagirdar R, et al. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease. Mol Pharmacol. 2017;92(6):694-706. DOI:10.1124/mol.117.110379
[2] Kharenko OA, et al. RVX-297- a novel BD2 selective inhibitor of BET bromodomains. Biochem Biophys Res Commun. 2016;477(1):62-67. DOI:10.1016/j.bbrc.2016.06.021

RVX297Supplier

Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Email
info@chemlin.com.cn
Nantong MYBio-pharm. Co., Ltd.
Tel
0513-85921823 18662920231
Email
sales@ntminyanmedical.com
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696，15000506266 15000506266
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com